Dupilumab Quality-of-Life Gains Varied by Child Age
While eczema severity improved across ages, younger children reported lower quality-of-life gains than teens.
Updated on Sept. 28, 2026 in Allergies
Live Poll
Do you trust that new medical treatments for children are equally effective across all age groups?
A study conducted in the Netherlands from 2019 to 2025 tracked 309 children and teens with atopic dermatitis treated with dupilumab. While the medication effectively reduced eczema severity and pruritus over three years, children younger than 6 reported lower quality-of-life improvements compared to older groups.
Why it matters
The findings highlight that atopic dermatitis impacts younger children differently, affecting their sleep and behavior in ways that may not be fully captured by standard treatment success metrics. Understanding these age-specific gaps helps parents and clinicians manage expectations for treatment outcomes.
In this longitudinal cohort study of 309 patients, eczema severity dropped from a baseline of 16.3 to 4.6 after 16 weeks, eventually reaching 3.4 after three years. While effective for skin symptoms, younger children reported significantly higher quality-of-life scores, indicating less perceived improvement than older peers.
The players
FDA
The United States agency responsible for approving drugs for use, including the 2022 authorization of dupilumab for children under 5.
American Academy of Dermatology
A professional medical society that establishes standard-of-care guidelines for the diagnosis and treatment of skin conditions.
The details
Dupilumab works by targeting specific proteins involved in the inflammatory process of atopic dermatitis. Patients received injections in the thigh, abdomen, or upper arm every 2 to 4 weeks, with 90% maintaining success at intervals up to 8 weeks. However, 63.1% experienced adverse effects, and over one-third developed dupilumab-associated ocular surface disease, which may complicate the treatment burden for younger children.
Timeline
2019-2025: The study treatment period occurred in the Netherlands.
2022: The FDA approved dupilumab for children younger than 5.
Early 2026: The American Academy of Dermatology issued updated treatment guidelines.
Health Landscape
This research provides a long-term look at biologic treatments for pediatric atopic dermatitis following the 2022 FDA approval of dupilumab for children under 5. It underscores a shift toward assessing not just skin clearance, but also the nuanced quality-of-life impacts across different developmental stages.
Parents considering biologic treatments for children should discuss the practical challenges of regular injections and the potential for ocular side effects with their physician. It is also worth asking how your doctor tracks quality-of-life improvements beyond standard skin-clearing metrics.
The takeaway
While dupilumab consistently clears skin symptoms over years of treatment, younger children may not report the same subjective quality-of-life benefits as older patients. If you are managing a child's eczema, discuss potential behavioral impacts and injection-related barriers with your dermatologist.
Further reading
For more on managing long-term treatment plans for skin conditions, visit Allergies.
Live Poll
Do you trust that new medical treatments for children are equally effective across all age groups?
